How many drugs treat Rheumatic heart disease?

Drug Landscape tracks 10 marketed treatments for Rheumatic heart disease (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/rheumatic-heart-disease.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Rheumatic heart disease — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rheumatic heart disease (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Rheumatic heart disease, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Decadron	dexamethasone	Generic (originally Merck)	Corticosteroid [EPC]	Annexin A1, Interleukin-4, Androgen receptor	1958-10-30
Medrol	methylprednisolone	Generic (originally Upjohn/Pfizer)	Glucocorticoid (corticosteroid)	Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor	1957-10-01
Prelone	prednisolone	Generic (originally Schering)	Glucocorticoid (corticosteroid)	Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1	1955-01-01
Deltasone	prednisone	Generic (originally Schering)	Corticosteroid [EPC]	Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor	1955-01-01
Solu-Cortef	hydrocortisone succinate	Pfizer	Corticosteroid	Glucocorticoid receptor	1955-01-01
Cortef	hydrocortisone	Generic (originally Merck/Upjohn)	Corticosteroid [EPC]	Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible	1952-01-01
Cortifoam	HYDROCORTISONE ACETATE	Pfizer	Corticosteroid	Corticosteroid-binding globulin	1951-01-01
prednison	prednison	Wen Zhang		Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor
Cortisol	Cortisol	University of Zurich		Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible
prednisolon	prednisolon	Hannover Medical School		Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 4 drugs in Rheumatic heart disease
Pfizer · 2 drugs in Rheumatic heart disease
Generic (originally Schering) · 2 drugs in Rheumatic heart disease
Generic (originally Upjohn/Pfizer) · 1 drug in Rheumatic heart disease
Hannover Medical School · 1 drug in Rheumatic heart disease
Leiden University Medical Center · 1 drug in Rheumatic heart disease
University of Zurich · 1 drug in Rheumatic heart disease
Wen Zhang · 1 drug in Rheumatic heart disease
Generic (originally Merck) · 1 drug in Rheumatic heart disease
Generic (originally Merck/Upjohn) · 1 drug in Rheumatic heart disease

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Rheumatic heart disease:

Cite this brief

Drug Landscape (2026). Rheumatic heart disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/rheumatic-heart-disease. Accessed 2026-06-10.

Rheumatic heart disease full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing